Alterations in eicosanoid levels during U937 bcl-xL tumour growth suppression and recovery in NU/NU mice in vivo—Involvement of phospholipase A2
| Autor: | Na Qiao, Denis Reynaud, Xiang Li, Mohamed Abdelhaleem, Peter Demin, Cecil R. Pace-Asciak |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Physiology
bcl-X Protein Mice Nude Antineoplastic Agents Bcl-xL Biology Phospholipase Biochemistry Mice 8 11 14-Eicosatrienoic Acid Phospholipase A2 In vivo Cell Line Tumor medicine Animals Humans Pharmacology Arachidonic Acid Antagonist Cell Biology Xenograft Model Antitumor Assays Tumor Burden Phospholipases A2 Mechanism of action Eicosanoid Cell culture Immunology Cancer research biology.protein Female medicine.symptom |
| Zdroj: | Prostaglandins & Other Lipid Mediators. 107:43-47 |
| ISSN: | 1098-8823 |
| DOI: | 10.1016/j.prostaglandins.2013.03.004 |
| Popis: | We report the effects of two anti-cancer drugs, PBT-4, an experimental antagonist to the pro-inflammatory hepoxilins, and Gleevec (STI-571), an anti-leukaemic drug, on eicosanoid tumour levels in immunodeficient mice (NU/NU) xenografted with the leukaemic cell line, U937 bcl-x L . After the tumours had grown to 80–100 mm 3 volume, an 8-day treatment with the drugs was initiated and the animals were monitored for 28 days. On various days, tumours were removed for measurement of 24 omega-6 eicosanoids. The data show remarkable direct correlation between inhibition of tumour AA release and 12-LOX products (including 12-HETE and hepoxilins) during PBT or STI treatment with tumour growth suppression. These findings suggest that inhibition of AA release may represent a novel underlying mechanism of action of PBT-4 (and STI) in vivo in suppressing tumour growth. As the PBT wears off, AA and 12-LOX products rise rapidly (Day 18) leading to the observed tumour growth spurt. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect